FierceBiotech1d
Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline
Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...
Strategic Focus and Financial Resilience: Terence Flynn’s Positive Outlook on Intellia Therapeutics
Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target ...
Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...
Intellia Therapeutics Restructures to Focus on Late-Stage Programs
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...